Get started

Stockanalysis

SeaHarvest is ready to float to R12.00The price has broken above the downtrend. There is a crucial level that was tested, and it might be where the buyers and Smart Money have filled their orders. Every other indicator is showing downside, but remember indicators are based on past momentum NOT the future. So we can expect the price to rally up before the next drop. But I'll let you know. 21>7 - Bearish RSI<50 - Bearish Target short term R12.00 ABOUT THE COMPANY SeaHarvest Group is a South African fishing and food processing company listed on the Johannesburg Stock Exchange (JSE) under the ticker symbol SHG. The company was founded in 1964 and is headquartered in Cape Town, South Africa. SeaHarvest specializes in the harvesting, processing, and marketing of a wide range of seafood products, including hake, prawns, squid, and value-added frozen seafood meals. Hake is the primary species for SeaHarvest, and the company is one of the largest hake fishing and processing companies in South Africa. South AFricans are very lucky to have Hake at your disposal. In Europe it's difficult to find. SeaHarvest operates a fleet of vessels that engage in both inshore and deep-sea fishing to ensure a sustainable supply of seafood. The company's fishing operations primarily target hake, a popular white fish species known for its mild flavor and versatility in cooking. SeaHarvest operates state-of-the-art seafood processing facilities that adhere to strict quality and food safety standards. The company's product range includes frozen whole fish, fillets, portions, seafood mixes, and coated products, catering to both retail and foodservice sectors.
JSE:SHGLong
by Timonrosso
Is there going to be a Big Bounce of 3M's stock ?Is there going to be a Big Bounce of 3M's stock ? This chart shows the weekly candle chart of 3M's stock since 2016. The graph overlays the top to bottom golden section of 2018. As shown in the figure, the recent low point of 3M's stock is just 4.000 in the top to bottom golden section, and the low point in 2018 and 2019 is just 2.000 and 2.618 in the golden section! Then, in the future, 3M's stock will face a Big Bounce trend, probably breaking through the low point in 2020 and reaching a new high in 2023!
NYSE:MMM
by Think_More
$PINC Punished for Lack of Working Capital?Premier health seems to be flashing some hands off signals at the moment.Based on an analysis of earnings against potential growth, fair value for NASDAQ:PINC would be around $40.38, but the stock is trading 54% below that target. They are even trading below the average analyst target of $33.40. These are signs that something is weighing on the market value of the firm. Potential Issues for Investors Include: 1. Cash to Equity at 4%: This suggests that the company has an insufficient amount of cash to fuel growth and handle liabilities. I would direct investor attention to the company's negative working capital and 20% drop in operating cash flows. 2. Shareholder Dilution: Premier seems to be constantly issuing new shares, which negates any market value that could be had from an increase in earnings. 3. Net Cash Negative: Total debt held by the company is down trailing 12 months, but still leaves the company with -$3.31 net cash per share over that same time period. Key Point: The company is over leveraged amidst tight financial conditions and margins in the healthcare space are dropping like a hot rock. This draws concern as the company has been working with negative working capital for 5 straight years. To mention a few bright spots, the company generating $84 in free cash flow for every $100 in earnings and seems to at least over the past 12 months be looking to reduce their debt. The company is projected to see earnings growth of 5.6% over the next 5 years, but is priced for no growth. Investors who look at this as a mispricing and buy today could see a push toward our forward looking valuations. This could yield as much as a 55% increase in the stock price. On the other hand the key question would be; can the company survive long enough to fix the problems? Investors who believe they will survive can look at this as a reasonable opportunity to buy ahead of any capital appreciation. Earnings are steady over the long term with over 4,400 member hospitals in their circle which should keep the money coming in. Worst case scenario, they become an acquisition target down the line, but in the mean time, I the market is sending signals that hands off is the policy. No growth value is definitely an enticing price point, but maybe a look at next quarter's earnings could provide more insight on the company's direction. PINC faces increased competition from other healthcare improvement companies, such as Optum and UnitedHealth Group. These companies are investing heavily in new technologies and solutions, which could put pressure on PINC's margins. PINC also faces a number of regulatory challenges, such as the implementation of the Affordable Care Act and the rising cost of healthcare. These challenges could make it difficult for PINC to grow its business and maintain its profitability. Income and cash flows have taken a step down in 2023. Cash flows are projected to continue to decline in 2024 and return to growth in 2025.
NASDAQ:PINC
by D1Finance
Will TSLA hit $410 by EOY ?Happy Friday everyone, and congratulations for making profit during this wave. As expected (see previous post). Looking at TSLA on the daily timeframe we see that the price of TSLA broke above the $207 and is testing the new resistance at $215. The trend remains bullish as long as the price creates higher highs. Of course there will be a correction, and for those who already sold and are waiting for a new buying opportunity, here are my buying levels to keep an eye on. The daily RSI is in the oversold territory, and we have a strong $215 resistance. However, no bearish candle formation as of this weeks close. For this year top price prediction, I believe that TSLA will test its ATH at $410. Why? We have a bullish flag formation that is now confirmed and the target (using log chart) is at $410. Going back to where I think the price of TSLA will correct, I think that we will see the price coming down to $173-$180. Even $165 is not out of possibilities which is the bottom of the symmetrical pattern. Fib golden pocket at $175. Thanks for reading, and Stay tuned. Please share your thoughts and comments, and don’t miss this trade if you missed my previous trade.
NASDAQ:TSLA
by EdgarTigranyan
3
Nice move up caught on the S&PHey traders! So here you will see this bullish candle where the blue arrow is pointed on the 4h chart on the S&P, this trade made an easy $15,700 with a more aggressive risk of 10% of capital but with basically 0% drawdown. My team and i noticed something big about this candle that 90% of traders miss and i mean big! especially if you trade options. Did you notice what was going on with this candle that was so big?. Follow for regular trade insights, ideas and more.
TVC:SPXLong
by SunTzu_V
PFE - Buy The Dip or Follow The Trend?When I began research for this post I expected to be giving the bull case for Pfizer. It's the type of stock I like - a household name oozing with quality and prestige, a strong moat, beaten up with strongly bearish sentiment with multiple factors pointing towards recovery, with short term technical support and long term positive fundamental outlook. I like to play the contrarian in the stock market and it often pays well. So what about Pfizer? Well, technically it's RSI oversold (or was on Thursday, before a small bump Friday) on virtually every timeframe from the 1 hour right through to the Weekly. Looking at Measured Moves, something I do regularly, it's down 19 points from it's swing high on Dec 14th 2022, exactly the same as big upswing from Feb 25th to Aug 18th 2021, and just short of the Oct 13th to Dec 20th 2021 swing of 21 points. Note that these 3 swings mentioned are the largest swings in Pfizer history, due to the growth and subsequent crash caused by COVID and the following recovery. We also have the potential for an area of support here, with the area around 36 having seen both support and resistance on a regular basis since 2016, and if we zoom out a year or 2 and look at Volume Profile, depending on where your set your Visible Range you're going to see the point of control landing between 34.5 - 36. Either the current price or just below. So what's the problem? There are a few. "Patent Cliffs" are always an issue for pharmaceutical companies, where after 20 years their patents expire and they have to face competition from generic brands entering the space. Five of Pfizer’s products face patent expiration in the next six years — Eliquis, an anticoagulant medication, Ibrance to treat breast cancer, Xeljanz for arthritis, Xtandi for prostate cancer, and Vyndaqel for transthyretin amyloid cardiomyopathy. Excluding Pfizer's COVID sales, these 5 products respresent 40% of the company's sales. Just this week, William Pao, Pfizer’s chief development officer raised concerns about antitrust regulators cracking down on Mergers and Acquisitions, notably with the blockage of Amgen's $28billion takeover of Horizon. This raises questions about Pfizer's proposed $43billion purchase of Seagen, and whether they too will come under regulator scrutiny. Financially, Pfizer's revenue is expected to meaningfully decline in 2023, mainly due to a drop in COVID-19 related sales. Analysts estimate the revenue to be around $68.1B, a 32% YoY decrease. Pfizer's adjusted EPS for FY23 is expected to be $3.37, down 49% YoY, according to Wall Street estimates. This is a company that since 2000 has traded as low as 12 in 2008, to as high as 61 at the peak of the COVID drug mania. While technically we do look likely to see a relief rally in the near term, this isn't a company I want to be exposed to. There is too much uncertainty, and while it may look cheap on the scale of the last few years, we must bear in mind that those years were drastically inflated due to COVID drugs that are no longer relevent to it's financials. Pfizer is coming back down to earth with a thud, and I think the company belongs in the 27-36 price range until we see more clarity on it's Seagen purchase and how much it's revenues are pilfered by competing generics. No play for me right now on Pfizer. This is the reality of stock analysis - you go down the rabbit hole, and ultimately most stocks are neither a buy or a sell. Just a "wait and see".
NYSE:PFE
by HayeTrading
10
Paypal - too cheap? PayPal's stock looks undervalued, trading at 6-year lows and a forward P/E ratio of 12.3, despite a strong Q1 performance with respectable transaction revenues, total payment volume, and growth in value-added services. Operating expenses are well-managed, contributing to substantial growth in operating income and earnings per share, while consensus estimates suggest mid-to-high teens EPS compound annual growth rate. Market concerns, such as PayPal's Q2 revenue guidance and increased competition, are offset by the Moderate Buy consensus rating, suggesting a 60.7% upside potential. The involvement of activist investor Elliott Management and the potential sale of the cross-border payment unit, Xoom, signal strategic changes that could enhance PayPal's performance. PayPal still rides the wave of the growth in e-commerce, with 12% payment volume increase in Q1 2023, and a rise in peer-to-peer transfers, demonstrating resilience in a challenging macroeconomic environment. The fundamentals of this company have become detached from the share price, making this a long term buy and hold with hugely asymmetrical risk/return profile. Shorter term, the move back to the highly developed Point of Control would represent over 20% growth, which I see as a high probability outcome within weeks.
NASDAQ:PYPLLong
by HayeTrading
8